“We also expect to backward integrate quickly so as to create a robust foundation for RNA based prophylactics and therapeutics for a wide range of diseases. This will strongly complement our Biologics work in the area of monoclonal antibodies,” Sharma added.

MegaLab also added that new cold chain infrastructure needs to be developed speedily to handle requirements for nationwide delivery of the vaccine.

Further, another initiative by the IIT Alumni Council — Mega Incubator — will create a Rs 75 crore sub-fund to support startup’s involved in indigenous raw materials for vaccines.

The India Vaccine Stack initiative, launched on Tuesday, has initiated the next round of funding of Rs 700 crores from Venture capital/ Private equity and social funds.

“We have been through the cost reduction and feature enhancement cycle in molecular diagnostics. Simple innovations like pool testing and lyophilisation helped drive down costs and eliminate wastage. Self-amplifying vaccines use the vaccine as a seed for the human body to produce the vaccine itself. This allows for a mRNA type vial of vaccine to be enough for a hundred people instead of ten people. This reduces cost by 90 per cent,” said Sanjay Nagi, Project Director of the India Vaccine Stack.

Source: IANS